Paragon 28, Inc. announced two changes to the composition of its Board of Directors. Quentin Blackford has joined the Company's Board of Directors and will serve the Company as Chairman of its Compensation Committee and as a member of its Audit Committee. Mr. Blackford has more than two decades of senior leadership experience with global medical device companies.

He currently serves as President, Chief Executive Officer, and Director of iRhythm Technologies. Prior to iRhythm Technologies, Mr. Blackford served at Dexcom, Inc. from 2017 to 2021, first as Chief Financial Officer and then as Chief Operating Officer. Prior to Dexcom, Mr. Blackford served at Nuvasive, Inc. from 2009 to 2017, including as Chief Financial Officer and as Head of Strategy and Corporate Integrity from 2014 to 2017.

Prior to 2009, Mr. Blackford served at Zimmer Biomet, Inc. Since October 2017, Mr. Blackford has also served as a member of the board of directors of Alphatec Holdings, Inc, where he serves on the compensation committee and audit committee. Mr. Blackford is a Certified Public Accountant (inactive) and received dual Bachelor of Science degrees in Accounting and Business Administration from Grace College. Effective as of August 1, 2022, Scott Drake resigned as a member of the Board of Directors (Board), the lead director of the Board and a member of the audit committee of the Board of Paragon 28, Inc. (the Audit Committee).

Mr. Drake's decision to resign was not the result of any disagreement with the Company, the Board, management, or any matter relating to the Company's operations, policies or practices.